Next Article in Journal
Self-Assembled AgNP-Containing Nanocomposites Constructed by Electrospinning as Efficient Dye Photocatalyst Materials for Wastewater Treatment
Next Article in Special Issue
Enhanced Delivery of Therapeutic siRNA into Glioblastoma Cells Using Dendrimer-Entrapped Gold Nanoparticles Conjugated with β-Cyclodextrin
Previous Article in Journal
Surface Decoration of ZnWO4 Nanorods with Cu2O Nanoparticles to Build Heterostructure with Enhanced Photocatalysis
Previous Article in Special Issue
Intratumoral Delivery of Doxorubicin on Folate-Conjugated Graphene Oxide by In-Situ Forming Thermo-Sensitive Hydrogel for Breast Cancer Therapy
Article Menu
Issue 1 (January) cover image

Export Article

Open AccessCommunication
Nanomaterials 2018, 8(1), 34; https://doi.org/10.3390/nano8010034

Inihibition of Glycolysis by Using a Micro/Nano-Lipid Bromopyruvic Chitosan Carrier as a Promising Tool to Improve Treatment of Hepatocellular Carcinoma

1
CNR NANOTEC-Istituto di Nanotecnologia, 73100 Lecce, Italy
2
Department of Mathematics and Physics “E. De Giorgi”, University of Salento, 73100 Lecce, Italy
3
Department of Biological and Environmental Sciences and Technologies (DiSTeBA), University of Salento, 73100 Lecce, Italy
4
Life Science Department, University of Modena e Reggio Emilia, 41121 Modena, Italy
Present Address: Sohag Cancer Center, 82511 Sohag, Egypt.
Present Address: Institute of Nanoscience and Nanotechnology, Kafrelsheikh University, 33516 Kafr ElSheikh, Egypt.
*
Author to whom correspondence should be addressed.
Received: 15 December 2017 / Revised: 5 January 2018 / Accepted: 8 January 2018 / Published: 10 January 2018
(This article belongs to the Special Issue Nanocolloids for Nanomedicine and Drug Delivery)
View Full-Text   |   Download PDF [3828 KB, uploaded 10 January 2018]   |  

Abstract

Glucose consumption in many types of cancer cells, in particular hepatocellular carcinoma (HCC), was followed completely by over-expression of type II hexokinase (HKII). This evidence has been used in modern pharmacotherapy to discover therapeutic target against glycolysis in cancer cells. Bromopyruvate (BrPA) exhibits antagonist property against HKII and can be used to inhibit glycolysis. However, the clinical application of BrPA is mostly combined with inhibition effect for healthy cells particularly erythrocytes. Our strategy is to encapsulate BrPA in a selected vehicle, without any leakage of BrPA out of vehicle in blood stream. This structure has been constructed from chitosan embedded into oleic acid layer and then coated by dual combination of folic acid (FA) and bovine serum albumin (BSA). With FA as specific ligand for cancer folate receptor and BSA that can be an easy binding for hepatocytes, they can raise the potential selection of carrier system. View Full-Text
Keywords: nanocarrier; glycolysis; hepatocellular carcinoma (HCC); bromopyruvate nanocarrier; glycolysis; hepatocellular carcinoma (HCC); bromopyruvate
Figures

Graphical abstract

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Supplementary material

Share & Cite This Article

MDPI and ACS Style

Hanafy, N.A.; Dini, L.; Citti, C.; Cannazza, G.; Leporatti, S. Inihibition of Glycolysis by Using a Micro/Nano-Lipid Bromopyruvic Chitosan Carrier as a Promising Tool to Improve Treatment of Hepatocellular Carcinoma. Nanomaterials 2018, 8, 34.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Nanomaterials EISSN 2079-4991 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top